Research programme: non-opioid analgesics - PixarBio

Drug Profile

Research programme: non-opioid analgesics - PixarBio

Alternative Names: Carbamazepine - PixarBio Corporation; Carbamazepine extended release - PixarBio Corporation; Extended-release liposomal carbamazepine - PixarBio Corporation; NeuroRelease; NeuroRelease SCI; NR-SCI; NR-TN; NR14

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PixarBio Corporation
  • Class Antiepileptic drugs; Dibenzazepines; Non-opioid analgesics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Postoperative pain
  • Research Epilepsy; Spinal cord injuries; Trigeminal neuralgia

Most Recent Events

  • 27 Feb 2018 PixarBio announces intention to submit NDA to the US FDA for Postoperative pain in late 2019
  • 27 Feb 2018 PixarBio announces intention to submit NDA for Trigemial neuralgia in early 2020
  • 15 Dec 2017 PixarBio Corporation intends to apply for fast track approval, via breakthrough therapy designation in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top